Zenas BioPharma reported third-quarter 2026 results and updates on its drug-development pipeline, with obexelimab’s regulatory review for IgG4-related disease (IgG4-RD) the company’s most advanced program. The FDA has set a May 27, 2027 target date for action on the U.S. application, while the European application has cleared an initial validation step.
The company also outlined upcoming clinical data milestones and reported $647.1 million in cash, cash equivalents and investments at September 30.
Key details
-
Obexelimab’s U.S. application is under FDA review. The FDA accepted the application for IgG4-RD and assigned a May 27, 2027 target action date. Zenas said the application is based on results from the global Phase 3 INDIGO trial.
-
The European review process is advancing. The European Medicines Agency validated Zenas’ marketing application for IgG4-RD, confirming it contains the materials needed to begin scientific assessment. The application includes INDIGO results and data on two ways of delivering obexelimab.
-
A more convenient delivery option may be added. Zenas reported bioequivalence between obexelimab delivered by prefilled syringe and by single-dose prefilled pen. The company plans to submit those data as a supplemental application if the original obexelimab application is approved.
-
More obexelimab data are due at a medical meeting. The company said open-label extension data from INDIGO will be presented in a late-breaking poster at ACR Convergence 2026. It also highlighted recent presentations on the drug’s potential to reduce glucocorticoid-associated toxicity and on results from an INDIGO vaccine sub-study. The release did not provide detailed results for those analyses.
-
Zenas expects two other clinical milestones in the fourth quarter. Topline results from the Phase 2 SunStone trial of obexelimab in systemic lupus erythematosus are on track for release. Initial Phase 1 data are also expected for ZB021, an oral IL-17AA/AF inhibitor.
-
Orelabrutinib data were presented in multiple sclerosis. Zenas reported that 24-week efficacy and safety data, along with pharmacokinetic analysis, from a Phase 2 trial in relapsing-remitting multiple sclerosis were presented at MSToronto2026. The release did not include the results themselves.
-
The company ended September with $647.1 million in cash, cash equivalents and investments. No revenue or net-loss figures were included in the supplied results text.
-
Jerald Korn was appointed chief legal and strategy officer. The release did not provide further details about the appointment.
Plain-English implications
Obexelimab is approaching a regulatory decision in the U.S., while its European review is getting underway. Zenas is also awaiting clinical readouts in lupus and early-stage data for ZB021, alongside its efforts to prepare for a potential obexelimab launch.